SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing significant downward pressure following disappointing quarterly delivery figures and intensifying competition in the EV sector. Investors are actively debating the company's long-term prospects as capital increasingly shifts toward anticipation of the upcoming SpaceX IPO.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is rallying following a strong quarterly earnings report that beat analyst expectations and provided a positive outlook for the year. The community is actively debating the stock's potential for a long-term turnaround fueled by the growing demand for energy storage and AI infrastructure, while some traders remain cautious about broader solar sector headwinds.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending following the announcement of subscription price increases across all U.S. tiers, a move that analysts view as a strategic leverage of pricing power to fuel content investment. While the community is split between bullish sentiment over potential revenue gains and frustration regarding rising costs, traders are closely watching the stock for a breakout above the key 100 level as volume and institutional interest pick up.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is experiencing significant trading activity driven by persistent market speculation regarding a potential acquisition by major tech and space players like Amazon or SpaceX. The community is actively debating the strategic value of the company's spectrum assets and the impact of Apple's existing partnership, with many long-term shareholders dismissing lower buyout rumors as undervaluation.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is currently experiencing intense volatility and downward pressure following a recent reverse split, leaving the community deeply divided between frustrated long-term shareholders and short-sellers profiting from the decline. Investors are actively debating the company's long-term viability, citing concerns over management's silence on financial guidance and a lack of major sports network partnerships, while some traders continue to look for potential short-squeeze opportunities.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Investors in Luckin Coffee are closely watching for potential catalysts like a possible relisting and the strategic implications of the Blue Bottle Coffee acquisition, while debating the impact of ongoing market volatility on the company's valuation. Community discussion is dominated by long-term holders expressing frustration over price suppression, even as others continue to accumulate shares based on strong growth fundamentals and a belief in a coming rebound.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is seeing a surge in investor attention as market sentiment shifts toward its critical role in AI infrastructure, with community focus centering on massive potential orders from major hyperscalers like Google and the company's pivot to high-volume semiconductor testing. Traders are closely watching for validation of these large-scale deployments, treating the stock as a high-conviction play on the structural expansion of AI-driven chip demand.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is surging following the FDA approval of VYKAT XR, the first treatment for hyperphagia in patients with Prader-Willi syndrome. Investors are actively discussing the stock's significant valuation shift from a clinical-stage biotech to a commercial-stage company, while monitoring the potential for a long-term buyout in a sector seeing heavy consolidation.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is currently trending as investors focus on the upcoming April 9th earnings report, with community sentiment split between high expectations for revenue growth from QNX-led automotive contracts and skepticism regarding historical guidance performance. Bulls are pointing to the integration of QNX in next-generation vehicle architectures as a major catalyst for long-term value, while shorts and skeptics continue to monitor the companys ability to move beyond stagnant revenue figures and prove sustained profitability.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix (ENVX) is currently experiencing high volatility as investors weigh the company's long-term potential in high-energy density batteries against ongoing manufacturing bottlenecks at its Malaysia facility. While community sentiment remains polarized, many participants are focused on the impact of a recent share repurchase program, the search for a major commercial purchase order, and whether the firm can successfully navigate production scaling to validate its silicon-anode technology.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Short Interest Down 39.8% in March

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) was the target of a significant decrease in short interest during the month of March. As of March 13th, there was short interest...

ProShares Ultra Nasdaq Biotechnology Declares Quarterly Dividend of $0.01 (NASDAQ:BIB)

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) announced a quarterly dividend on Tuesday, March 24th. Shareholders of record on Wednesday, March 25th will be given a dividend of 0.0071 per share...

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Cross Below 50 Day Moving Average - What's Next?

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Cross Below 50 Day Moving Average - Time to Sell...

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Pass Below 50 Day Moving Average - Time to Sell?

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Share Price Cross Below 50-Day Moving Average - Here's Why...

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Short Interest Down 27.9% in January

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) was the recipient of a large decrease in short interest in January. As of January 30th, there was short interest totaling 21,087...

Short Interest in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Declines By 29.2%

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) saw a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling 28,385...

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) to Issue Quarterly Dividend of $0.13

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) declared a quarterly dividend on Tuesday, December 23rd. Shareholders of record on Wednesday, December 24th will be paid a dividend of 0.1346 per...

<ul class="summary-bullets"><li>With Abivax now trading as a strategic asset rather than a pure clinical story, takeover interest from a deep-pocketed pharma player introduces a potential valuation floor.</li><li>At roughly an $11 billion market cap, the stock is priced with strong odds of UC success and meaningful commercialization.</li><li>There is still room for upside if Crohn’s disease data validate a broader, multi-indication franchise.</li></ul>French clinical-stage biotech Abivax (ABVX) had an uneventful Nasdaq debut in October 2023 and spent much of its early public life flying under the radar. That changed abruptly this year after a single clinical data readout flipped the narrative — a familiar inflection point in biotech investing.&nbsp;<a href="https://stocktwits.com/symbol/ABVX">Abivax’s stock</a> is up nearly 1,900% year-to-date, making it the best-performing biotech stock&nbsp;on U.S. exchanges.Adding fuel to the mid-year momentum, Eli Lilly (LLY) has emerged as a potential suitor, with market chatter suggesting the pharma giant is circling the smaller biotech. French media outlet La Lettre reported earlier this week that a delegation of Lilly executives met with the French Treasury and&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.lalettre.fr/fr/entreprises_sante/2025/12/22/l-americain-eli-lilly-en-operation-seduction-a-bercy-pour-racheter-la-biotech-abivax,110583257-art">submitted</a> an acquisition proposal for Abivax.How does this shift the investment thesis around this smaller name? What was once a high-beta, data-driven clinical bet increasingly looks like a strategic M&amp;A optionality trade, with a potential floor under the stock—at least in the near term.<img src="https://news.stocktwits-cdn.com/Abivax_since_IPO_png_b0a5af2a71.webp" alt="Abivax since IPO.png">Source: Koyfin<h2 class="st-heading-2">From Clinical Breakout to Strategic Asset</h2>For all the hype around the name, Abivax is still&nbsp;more or less a one-trick pony. Its lone pipeline asset and lead candidate, Obefazimod, is an immunomodulator that is being evaluated for multiple indications. The indication that is&nbsp;most developed is moderately to severely active ulcerative colitis (UC).&nbsp;Obefazimod acts by enhancing the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response. Inflammatory Bowel Disease (IBD), a broader term used to refer to chronic conditions such as UC and Crohn’s disease, is an autoimmune response. The immune system mistakenly attacks the gut, causing inflammation and damage to the digestive tract, leading to symptoms such as diarrhea, abdominal pain, weight loss and fatigue.&nbsp;UC affects the large intestine and rectum, causing ulcers on the inner lining, and Crohn’s disease can affect any part of the gastrointestinal tract and inflames the entire bowel wall.&nbsp;Is the condition such a big opportunity? By Abivax’s own account, it seems so. In a corporate presentation, the company said, citing Evaluate data, that IBD prevalence was 3.6 million in the G7 nations in 2024, with roughly 64% in the U.S. The prevalence is expected to grow at a modest 4% pace over the next six years. Worldwide IBD drug sales in 2024 are estimated at $23.7 billion, with 70% from the U.S.<h4 class="st-heading-4" style="text-align:center;">Worldwide IBD Sales&nbsp;</h4><figure class="image"><img style="aspect-ratio:661/535;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_24_at_1_48_03_AM_png_2f93920926.webp" alt="Screenshot 2025-12-24 at 1.48.03 AM.png" width="661" height="535"></figure>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; Source: AbivaxThe current treatment options include:-Interleukin-23 selective inhibitors (block the action of pro-inflammatory cytokine protein interleukin-23)-Sphingosine 1-phosphate (S1P) modulators such as ozanimod and etrasimod (target proteins linked to inflammation on immune cells and stop them from leaving the lymph nodes)-Janus Kinase (JAK) inhibitors (stop several types of pro-inflammatory cytokines from forming)Abivax projects Obefazimod as a differentiated treatment option compared to existing therapies, by enhancing the expression of microRNA-124, a natural regulator of the inflammatory response. The mode of administration is also convenient: an oral once-daily pill with a favorable long-term safety profile.<h2 class="st-heading-2">Wall Street Analysts’ Optimism Abounds</h2>Following topline data from two Phase 3 studies showing the candidate met the primary and secondary endpoints, Abivax stock received love from several Wall Street firms, with Morgan Stanley upgrading the stock to an ‘Overweight,’ according to the Fly.&nbsp;The pooled placebo-adjusted clinical remission for the 50mg dose of 16.4% came in above the roughly 15% bar that Morgan Stanley analysts estimated based on their conversations with investors and experts. The analyst also expected improved odds of success across UC and Crohn's.&nbsp; Guggenheim analysts estimated Obefazimod’s value at $7 billion to $10 billion.Piper Sandler analysts said following the Phase 3 data, they have layered in revenue in early-line UC. This doubles its U.S. UC estimate to 2.66 billion euros ($3.14 billion) in 2035, suggesting there could be significant upside to the stock ahead of key data events.Abivax presented the results of the two late-stage studies at the United European Gastroenterology (UEG) Meeting in Berlin in early October. Citizen JMP analysts, who upped their price target ahead of the event, said the data reinforce Obefazimod’s efficacy and increase conviction in its multi-billion-dollar sales potential. Guggenheim named Abivax as a “Best Idea” and upped its price target to $150.&nbsp;Last month, Wolfe Research initiated coverage of the stock with an ‘Outperform’ rating and a $176 price target. The firm based its optimistic assessment on its belief that the company’s odds of success in Crohn’s disease may be higher than those of UC. Crohn’s readout would be a better catalyst in 2026, it added.According to Koyfin, the average analyst price target for Abivax stock is $138.35, implying a 22% downside from current levels. Of the five analysts covering the stock, four have either a ‘Buy’ or a ‘Strong Buy’ rating, and one remains on the sidelines.<h2 class="st-heading-2">Retail Jump Onto Bullish Bandwagon</h2>The Abivax stock stream on Stocktwits has attracted a large following, with the watcher count jumping over 5,500% in the past year. The 30-day message volume is up 2,100%.&nbsp;Retail sentiment toward the stock was ‘extremely bullish’ as of early Wednesday, and it has mainly remained upbeat throughout the year. A bullish&nbsp;<a href="https://stocktwits.com/jeremy0916/message/639921688">watcher</a> has already set his sights on the $230 level for a stock that ended Tuesday’s session at $138.35.<figure class="image"><img style="aspect-ratio:724/433;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_24_at_3_01_43_AM_png_3c8d4a0547.webp" alt="Screenshot 2025-12-24 at 3.01.43 AM.png" width="724" height="433"></figure><h2 class="st-heading-2">Key Catalysts Investors Are Watching</h2>Fresh off its addition to the Nasdaq Biotechnology Index, Abivax is entering a catalyst-rich phase. The topline results from an ongoing 44-week maintenance trial, dubbed ABTECT-107, are expected to be read out in the second quarter of 2026. The company also plans to release topline data from the Phase 2 Crohn’s Disease study in the second half of next year.<h2 class="st-heading-2">Why Lilly Might Be Interested</h2>Obefazumod could be a better fit in Lilly’s immunology franchise, which includes Omvoh, an IL-23 inhibitor, used as a second-line treatment for adults with moderately to severely active UC and Crohn’s disease. It is administered as an IV infusion. Lilly also acquired Morphic Pharma, thereby adding an oral integrin blocker for UC.Abivax’s current market valuation is roughly $11 billion. The company’s cash position as of Sept. 2025 is 589.7 million euros, and the company said it has a cash runway into the fourth quarter of 2027.&nbsp;Whether that Lilly deal materializes or not, Abivax enters 2026 with elevated expectations, higher stakes, and far more eyes on the name than ever before.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-s-worst-year-in-four-decades-may-end-thanks-to-a-weight-loss-pill/cLepFr2REuw">Novo Nordisk’s Worst Year In Over Four Decades May Be Ending — Thanks To A Weight-Loss Pill</a>

In this photo illustration, the Abivax logo is seen displayed on a smartphone screen.

How Abivax Went From Biotech Nobody To M&A Bullseye After A Single Blockbuster Readout This Year

A 1,900% rally, Phase 3 wins, and takeover chatter around Eli Lilly have transformed Abivax from a risky clinical bet into a strategic asset with real optionality.

Equity

A 1,900% rally, Phase 3 wins, and takeover chatter around Eli Lilly have transformed Abivax from a risky clinical bet into a strategic asset with real optionality.


ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Shares Cross Above 50 Day Moving Average - Here's Why

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Pass Above 50 Day Moving Average - What's Next...

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Pass Above 50 Day Moving Average - Time to Sell...

BIB
ProShares Ultra Nasdaq Biotechnology

Feed

News

Sentiment

Fundamentals

Info

Latest BIB News

BIBProShares Ultra Nasdaq Biotechnology